MW-150 (MW01-18-150SRM) is a selective, orally active, neurotransmitter p38α MAPK inhibitor with a Ki of 101 nM. It inhibits the ability of endogenous p38α MAPK to phosphorylate the endogenous substrate MK2 in activated glia.
MW-150 (MW01-18-150SRM) is a selective, orally active, neurotransmitter p38α MAPK inhibitor with a Ki of 101 nM. It inhibits the ability of endogenous p38α MAPK to phosphorylate the endogenous substrate MK2 in activated glia.
